Dasatinib News and Research

RSS
Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.
New presentations on neuroendocrine tumors at ESMO 12th World Congress on Gastrointestinal Cancer

New presentations on neuroendocrine tumors at ESMO 12th World Congress on Gastrointestinal Cancer

FDA approves new indication for Tasigna in treatment of rare blood cancer

FDA approves new indication for Tasigna in treatment of rare blood cancer

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

CytRx granted U.S. Patent for bafetinib

CytRx granted U.S. Patent for bafetinib

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

Study explores genetic imbalances that give rise to childhood brain tumors

Study explores genetic imbalances that give rise to childhood brain tumors

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

EpiCept invites stockholders to attend Annual Meeting

EpiCept invites stockholders to attend Annual Meeting

CytRx' bafetinib receives EMEA COMP positive opinion for treatment of CML

CytRx' bafetinib receives EMEA COMP positive opinion for treatment of CML

Cytrx to commence Phase 2 trial of bafetinib for advanced prostate cancer

Cytrx to commence Phase 2 trial of bafetinib for advanced prostate cancer

Study: Trial vaccine eliminates residual cancer cells in CML patients

Study: Trial vaccine eliminates residual cancer cells in CML patients

Researchers discover key reason why form of leukemia progresses from chronic phase to blast crisis

Researchers discover key reason why form of leukemia progresses from chronic phase to blast crisis

Preliminary studies show cancer vaccine may reduce tumor cells in CML patients

Preliminary studies show cancer vaccine may reduce tumor cells in CML patients

CML patients on nilotinib or dasatinib drug achieve better response than imatinib drug

CML patients on nilotinib or dasatinib drug achieve better response than imatinib drug